Those in Saskatchewan living with cystic fibrosis are now eligible for Alyftrek, a medication that improves lung function. Coverage for the drug has extended to cystic fibrosis (CF) patients ages six and older who meet the medical criteria as of Aug. 1. CF is a genetic disease that damages the lungs and digestive system. According to the Government of Saskatchewan, it’s effective for those who have one of 266 different rare genetic mutations that cause CF. “Our government is pleased to cover the cost of this new treatment for Saskatchewan patients with cystic fibrosis,” said Health Minister Jeremy Cockrill in a news release. “Alyftrek has been shown to improve quality of life in patients with CF, so expanding coverage puts CF patients first by helping them to lead healthier lives.” There is currently no cure for CF, but the province says Alyftrek controls symptoms and slows the progression of the disease. The province says coverage for the drug is the result of a July 2025 Health Canada recommendation followed by successful pricing negotiations through the pan-Canadian Pharmaceutical Alliance in July 2026. The province also covers other CF medications that treat specific genetic forms, including Tikafta, Orkambi and Kalydeco. According to the government, the addition of Alyftrek makes more than 95 per cent of eligible patients in Saskatchewan candidates for therapy. With those with CF or parents/guardians who have children living with CF are encouraged to speak with their physician if they believe they or their loved ones may benefit from Alyftrek therapy. There are nearly 150 CF patients in Saskatchewan and more than 4,500 patients in Canada, according to the Canadian Cystic Fibrosis Registry.
